<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Cotticelli MG</submitter><funding>Children&amp;apos;s Hospital of Philadelphia</funding><funding>Hamilton and Finneran Families</funding><funding>NIDDK NIH HHS</funding><funding>Children's Hospital of Philadelphia</funding><funding>NINDS NIH HHS</funding><funding>Friedreich&amp;apos;s Ataxia Research Alliance</funding><funding>Friedreich's Ataxia Research Alliance</funding><pagination>dmm049497</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9637271</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16(5)</volume><pubmed_abstract>Friedreich ataxia, the most common hereditary ataxia, is a neuro- and cardio-degenerative disorder caused, in most cases, by decreased expression of the mitochondrial protein frataxin. Cardiomyopathy is the leading cause of premature death. Frataxin functions in the biogenesis of iron-sulfur clusters, which are prosthetic groups that are found in proteins involved in many biological processes. To study the changes associated with decreased frataxin in human cardiomyocytes, we developed a novel isogenic model by acutely knocking down frataxin, post-differentiation, in cardiomyocytes derived from induced pluripotent stem cells (iPSCs). Transcriptome analysis of four biological replicates identified severe mitochondrial dysfunction and a type I interferon response as the pathways most affected by frataxin knockdown. We confirmed that, in iPSC-derived cardiomyocytes, loss of frataxin leads to mitochondrial dysfunction. The type I interferon response was activated in multiple cell types following acute frataxin knockdown and was caused, at least in part, by release of mitochondrial DNA into the cytosol, activating the cGAS-STING sensor pathway.</pubmed_abstract><journal>Disease models &amp; mechanisms</journal><pubmed_title>Acute frataxin knockdown in induced pluripotent stem cell-derived cardiomyocytes activates a type I interferon response.</pubmed_title><pmcid>PMC9637271</pmcid><funding_grant_id>P30 DK019525</funding_grant_id><funding_grant_id>R01 NS124640</funding_grant_id><pubmed_authors>Rozo AV</pubmed_authors><pubmed_authors>Napierala JS</pubmed_authors><pubmed_authors>Yang W</pubmed_authors><pubmed_authors>Cotticelli MG</pubmed_authors><pubmed_authors>Wilson RB</pubmed_authors><pubmed_authors>Chen J</pubmed_authors><pubmed_authors>Doliba NM</pubmed_authors><pubmed_authors>Xia S</pubmed_authors><pubmed_authors>Truitt R</pubmed_authors><pubmed_authors>Tobias JW</pubmed_authors><pubmed_authors>Lee T</pubmed_authors><pubmed_authors>Napierala M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Acute frataxin knockdown in induced pluripotent stem cell-derived cardiomyocytes activates a type I interferon response.</name><description>Friedreich ataxia, the most common hereditary ataxia, is a neuro- and cardio-degenerative disorder caused, in most cases, by decreased expression of the mitochondrial protein frataxin. Cardiomyopathy is the leading cause of premature death. Frataxin functions in the biogenesis of iron-sulfur clusters, which are prosthetic groups that are found in proteins involved in many biological processes. To study the changes associated with decreased frataxin in human cardiomyocytes, we developed a novel isogenic model by acutely knocking down frataxin, post-differentiation, in cardiomyocytes derived from induced pluripotent stem cells (iPSCs). Transcriptome analysis of four biological replicates identified severe mitochondrial dysfunction and a type I interferon response as the pathways most affected by frataxin knockdown. We confirmed that, in iPSC-derived cardiomyocytes, loss of frataxin leads to mitochondrial dysfunction. The type I interferon response was activated in multiple cell types following acute frataxin knockdown and was caused, at least in part, by release of mitochondrial DNA into the cytosol, activating the cGAS-STING sensor pathway.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 May</publication><modification>2026-05-27T23:42:40.576Z</modification><creation>2024-12-04T12:30:22.593Z</creation></dates><accession>S-EPMC9637271</accession><cross_references><pubmed>36107856</pubmed><doi>10.1242/dmm.049497</doi></cross_references></HashMap>